...
search icon
auph-img

Aurinia Pharmaceuticals Inc Share Price

AUPH
NMQ
$14.31
+$0.08
(0.56%)
1D
Industry: Biotechnology Sector: Health Care

Aurinia Pharmaceuticals Inc Analyst Forecast

Aurinia Pharmaceuticals Inc Share Price Chart

Aurinia Pharmaceuticals Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.88B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
25.4107
Volume info-icon
This is the total number of shares traded during the most recent trading day.
581.97K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.54
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.55 L
$16.54 H
$14.31

About Aurinia Pharmaceuticals Inc, Common Stock

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. more

Industry: BiotechnologySector: Health Care

Aurinia Pharmaceuticals Inc Stock Returns

Time FrameAUPHSectorS&P500
1-Week Return-2.27%1.51%-1.5%
1-Month Return-3.79%1.46%0.6%
3-Month Return-8.13%3.94%2.43%
6-Month Return16.45%16.03%6.01%
1-Year Return78.1%9.1%11.48%
3-Year Return73.75%19.46%67.52%
5-Year Return-10.78%35.29%73.75%
10-Year Return495.4%137.42%254.46%

Aurinia Pharmaceuticals Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue50.12M45.60M134.03M175.51M235.13M[{"date":"2020-12-31","value":21.31,"profit":true},{"date":"2021-12-31","value":19.4,"profit":true},{"date":"2022-12-31","value":57,"profit":true},{"date":"2023-12-31","value":74.64,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue50.33M1.09M5.66M14.15M28.25M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":2.17,"profit":true},{"date":"2022-12-31","value":11.25,"profit":true},{"date":"2023-12-31","value":28.11,"profit":true},{"date":"2024-12-31","value":56.13,"profit":true}]
Gross Profit50.12M44.51M128.37M161.37M206.88M[{"date":"2020-12-31","value":24.23,"profit":true},{"date":"2021-12-31","value":21.52,"profit":true},{"date":"2022-12-31","value":62.05,"profit":true},{"date":"2023-12-31","value":78,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin100.00%97.61%95.77%91.94%87.99%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.61,"profit":true},{"date":"2022-12-31","value":95.77,"profit":true},{"date":"2023-12-31","value":91.94,"profit":true},{"date":"2024-12-31","value":87.99,"profit":true}]
Operating Expenses154.41M225.25M239.84M253.06M211.57M[{"date":"2020-12-31","value":61.02,"profit":true},{"date":"2021-12-31","value":89.01,"profit":true},{"date":"2022-12-31","value":94.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":83.61,"profit":true}]
Operating Income(104.29M)(180.74M)(111.47M)(91.69M)(4.69M)[{"date":"2020-12-31","value":-10429000000,"profit":false},{"date":"2021-12-31","value":-18073500000,"profit":false},{"date":"2022-12-31","value":-11147000000,"profit":false},{"date":"2023-12-31","value":-9169100000,"profit":false},{"date":"2024-12-31","value":-468700000,"profit":false}]
Total Non-Operating Income/Expense3.03M1.06M10.24M28.09M24.27M[{"date":"2020-12-31","value":10.79,"profit":true},{"date":"2021-12-31","value":3.77,"profit":true},{"date":"2022-12-31","value":36.43,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":86.39,"profit":true}]
Pre-Tax Income(102.77M)(180.21M)(106.35M)(77.47M)7.45M[{"date":"2020-12-31","value":-1379.89,"profit":false},{"date":"2021-12-31","value":-2419.52,"profit":false},{"date":"2022-12-31","value":-1427.93,"profit":false},{"date":"2023-12-31","value":-1040.13,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income Taxes(94.00K)760.00K1.83M551.00K1.70M[{"date":"2020-12-31","value":-5.14,"profit":false},{"date":"2021-12-31","value":41.58,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":30.14,"profit":true},{"date":"2024-12-31","value":92.78,"profit":true}]
Income After Taxes(102.68M)(180.97M)(108.18M)(78.02M)5.75M[{"date":"2020-12-31","value":-1785.12,"profit":false},{"date":"2021-12-31","value":-3146.14,"profit":false},{"date":"2022-12-31","value":-1880.74,"profit":false},{"date":"2023-12-31","value":-1356.4,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income From Continuous Operations(102.68M)(180.97M)(108.18M)(77.19M)5.75M[{"date":"2020-12-31","value":-1785.12,"profit":false},{"date":"2021-12-31","value":-3146.14,"profit":false},{"date":"2022-12-31","value":-1880.74,"profit":false},{"date":"2023-12-31","value":-1341.99,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(102.68M)(180.97M)(108.18M)(78.02M)5.75M[{"date":"2020-12-31","value":-1785.12,"profit":false},{"date":"2021-12-31","value":-3146.14,"profit":false},{"date":"2022-12-31","value":-1880.74,"profit":false},{"date":"2023-12-31","value":-1356.4,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
EPS (Diluted)(0.74)(1.41)(0.76)(0.54)0.09[{"date":"2020-12-31","value":-822.22,"profit":false},{"date":"2021-12-31","value":-1566.67,"profit":false},{"date":"2022-12-31","value":-844.44,"profit":false},{"date":"2023-12-31","value":-600,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]

Aurinia Pharmaceuticals Inc Ratios

Aurinia Pharmaceuticals Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

AUPH
Cash Ratio 4.62
Current Ratio 5.76
Quick Ratio 5.17

Aurinia Pharmaceuticals Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AUPH
ROA (LTM) 9.41%
ROE (LTM) 20.65%

Aurinia Pharmaceuticals Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AUPH
Debt Ratio Lower is generally better. Negative is bad. 0.31
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.69

Aurinia Pharmaceuticals Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AUPH
Trailing PE 25.41
Forward PE 18.48
P/S (TTM) 7.06
P/B 5.13
Price/FCF 42
EV/R 6.03
EV/Ebitda 15.48
PEG NM

FAQs

What is Aurinia Pharmaceuticals Inc share price today?

Aurinia Pharmaceuticals Inc (AUPH) share price today is $14.31

Can Indians buy Aurinia Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Aurinia Pharmaceuticals Inc (AUPH) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AUPH stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Aurinia Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Aurinia Pharmaceuticals Inc (AUPH) via the Vested app. You can start investing in Aurinia Pharmaceuticals Inc (AUPH) with a minimum investment of $1.

How to invest in Aurinia Pharmaceuticals Inc shares from India?

You can invest in shares of Aurinia Pharmaceuticals Inc (AUPH) via Vested in three simple steps:

  • Click on Sign Up or Invest in AUPH stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Aurinia Pharmaceuticals Inc shares
What is Aurinia Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Aurinia Pharmaceuticals Inc (AUPH) is $16.54. The 52-week low price of Aurinia Pharmaceuticals Inc (AUPH) is $6.55.

What is Aurinia Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Aurinia Pharmaceuticals Inc (AUPH) is 25.4107

What is Aurinia Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Aurinia Pharmaceuticals Inc (AUPH) is 5.13

What is Aurinia Pharmaceuticals Inc dividend yield?

The dividend yield of Aurinia Pharmaceuticals Inc (AUPH) is 0.00%

What is the Market Cap of Aurinia Pharmaceuticals Inc?

The market capitalization of Aurinia Pharmaceuticals Inc (AUPH) is $1.88B

What is Aurinia Pharmaceuticals Inc's stock symbol?

The stock symbol (or ticker) of Aurinia Pharmaceuticals Inc is AUPH

How Can Investors Use Aurinia Pharmaceuticals Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Aurinia Pharmaceuticals Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Aurinia Pharmaceuticals Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Aurinia Pharmaceuticals Inc shares for Indian investors?

When investing in Aurinia Pharmaceuticals Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Aurinia Pharmaceuticals Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Aurinia Pharmaceuticals Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Aurinia Pharmaceuticals Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Aurinia Pharmaceuticals Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top